Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Nucana ( (NCNA) ).
On January 6, 2026, NuCana announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026, elevating her from her previous role as Senior Vice President of Clinical Operations. Bruce brings over 25 years of oncology R&D and global clinical development experience from leadership positions at Nexus Oncology, Chiltern, Veristat and as a consultant to U.S. biotech companies, and is expected to play a key role in advancing NuCana’s oncology pipeline, including the Phase 1/2 expansion study of NUC-7738 in melanoma, preparations for a potential registration strategy for NUC-7738, and further work to define the mode of action and target indications for NUC-3373, at a time when the company highlights an anticipated cash runway extending into 2029, underscoring both operational continuity and long-term strategic focus for stakeholders.
The most recent analyst rating on (NCNA) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Neutral.
The score is driven primarily by weak financial performance (no revenue, continued losses, and negative cash flow despite low leverage). Technicals add pressure with a bearish trend (below key moving averages and negative MACD). Valuation offers limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, focused on improving cancer treatment outcomes by applying its proprietary ProTide technology to transform widely used nucleoside analog chemotherapy agents into more effective and better-tolerated medicines. Its pipeline includes NUC-7738, a novel anti-cancer agent currently in Phase 2 studies as both monotherapy and in combination with pembrolizumab, and NUC-3373, a new chemical entity derived from 5-fluorouracil that has been evaluated in Phase 1b/2 studies in combination with immunotherapy and chemotherapy across advanced solid tumors and lung cancer, as the company assesses further clinical development opportunities.
Average Trading Volume: 190,552
Technical Sentiment Signal: Sell
Current Market Cap: $15.4M
For an in-depth examination of NCNA stock, go to TipRanks’ Overview page.